

Underlying effect External ulcers and skin lesions, Diabetic gangrene disinfection wound cleansing improved wound healing Arterial circulatory disturbonces, Angiopathia activation of red blood cell metabolism with improved oxygen release activation of enzymotic antioxidants and radical scavengers Chronic inflammatory diseases, collist, practilis, activated anthrosis activated anthrosis activated activation of antioxidant enzymes and radical scovengers activation of immunocompetent cells and cartilage cells eg with release of TGF.8



Chronic inflammatory diseases of the joints, myofascial triggerpoints and disk hernia rei indications for intraanticular and perioriticator as well as intromaterial and perioriticator as well as intromaterial and intradisciol coone injections in the concentration range of 2 to 10, max.
20 µg/ml according to application form; exact coone concentrations are a prerequirement.



DR. HÄNSLER OZONOSAN boardcase




As with all OZONOSAN units, the concentration measuring unit of the OZONOSAN boardcase constitutes a basic element of quality assurance.

As an absolutely mobile unit in its elegant but functional trailey, it has quickly gained general acceptance in pain therapy (also in sports medicine), and is used for house withs and as a reserve unit. With its system for all systemic applications as well as topical injection techniques.

The integrated vacuum pump with variable negative pressure settings is particularly suitable for low-pressure O_3 gas applications in decubitus or diabetic ulcars, for example with patients confined to bed in homes and narriag care units.

DR. HÄNSLER OZONOSAN




☐ Transcutaneous O₃ gas immersion and low pressure azone gas application acc. to Werkmeister

□ The microbubble system in major auto-haemotherapy as extracorporal blood treatment. With or without citrate as anticoagulant. □ Topic injection techniques with accore-resistant, siliconised disposable syringes and bacterial filters (0.2 µm)

Angiopathias, arterial circulatory distur-bances, chronic inflammatory diseases, all forms of chronic hepatitis, and as a

☐ Rectal O₂/O₂ gas insufflation

Indications same as for Major Auto-Haemotherapy MAH, especially in chronic forms of hepatitis, and intestinal conditions such as colitis and proctitis



t in min

DR. HANSLEDZONOSAN

1958	Dr. Joachim Hänzler registers OZONOSAN® as a trade mark: the first medical ozone generator with exact concentration dosage control: OZONOSAN PM 58
1959	The first patent is granted.
1968	Major ozone autohaemotherapy as extracorporeal blood treatment replaces intravascular administration
1979	The first TÜV-certificate of safety "GS" by TÜV Cologne
1980-1995	New product line: OZONOSAN PM 80, 83 and 90 appears on the market
1985	"Medical Ozone/Oxygen Therapy" first published as practical handbook
1990-1995	The microbubble system for major ozone autohaematherapy is patented throughout Europe, other patents follow
1995-2006	The "Ozone Handbook" (ecomed publisher) with the latest scientific literature, published in loose-leaf form, rapidly became the standard work
1998-2008	Italian pirate copies compel Dr. Hänsler Co. to develop a comple- tely new OZONOSAN concept: The photometric azone concentra- tion measurement and control system is integrated: OZONOSAN alpha plus, photonik and boardcase
1998	Certification in accordance with the new European Guideline 93/42/EEC by Med. Cert. TÜV Cologne
2012	The GUIDELINES FOR OZONE THERAPY are published in "Ozone: Science & Engineering", the scientific journal of the International Ozone Association IOA
2014/15	The COMBI-SET, a new device for the Major autohemotherapy has been accepted as EU patent
2016	CYTOZON, the 3rd generation of the dental azone unit, appears on

the incircular

2016 — Geliscal evaluation and evidence classification of the systemic azone
therapy is published and honoured with the HMAYER KOSEN AWARD
by the lementational Classe Macadistics (NA in 2016)

2018 — 60 years anniversory of OZONOSAN

The bus of Ozone in Medicine, in Practical Handbook, is published
as a completely revised and expanded edition in english, german
and sponsh.

Medical azone as bioregulator in its "low dose concept" form, is an established and scientifically founded treatment concept in comple-mentary medicine which is not only well documented but also subject of publications on an international platform.

... with continuous measurement and control of ozone concentrations, integrated as a standard element in all OZONOSAN generators. This provides optimum safety in therapy and patient care ...

... in addition to which our trained and dedicated me-dical device consultants are ready to help with thera-py and application techniques.

You will find practical guidance and receive a scientific foundation in all uses of medical ozone at our workshops and congresses in Germany and abroad.

The OZONOSAN therapy system is complemented by our training guidelines and various handbooks; these are nowadays recognized as standard literature in the context of relevant studies, treatment concepts and dosage recommendations for all users of medical azone.

Where ozone/oxygen therapy is involved, we provide scientific know-how, competent advice, experience and expert cooperation in all medical, technical and practical aspects.

We look forward to hearing from you.

Yours Sincerely. enje

Dr. Renate Viebahn-Hänsler

DR. HÄNSLER OZONOSAN alphaplus



Angiopathias, particularly diabetic angio-pathia, arterial circulatory disturbances and diabetic foot are classical indications for acome/oxygen therapy. When Oy/Oy, is applied in a complementary and differentiated form, remarkably suc-cessful results are obtained.

Apart from local ozone applications (disinfection, wound healing) systemic therapy in the form of molor ozone infasion via the patient's own blood or rectal insuffiction they make use of the antimiferamentary and circulation-enhancing effect of O₂ (activation of the artifiction of the artifictio

OZONOSAN



The OZONOSAN alpha plus with its continuous and accurate measurement of a controlled O₃ supply is ideally adapted for the whole treatment range (see table above):

■ The OZONOSAN alpha plus supplies the broad concentration range from 1 µg/ml up to > 100 µg/ml, which corresponds to 0.05 = 5 volume % ozone.

And the OZONOSAN alpha plus produces ozonized water with optimum ozone dose and optimum saturation level.

■ With its controlled volume flow, controlled hightech pump units and high charge, autoregenerative catalyzer systems, the alpha plus is the ideal prerequirement for effective local ozone treatment.

DR. HÄNSLER OZONOSAN photonik



At the very least, complementary oncology in a holistic medical context produces a considerable improvement in the general condition of the patients involved, reduces the side-effects of chemotherapy and radiation and thus contributes to life quality in a very real sense.

In fact, ozone therapy represents a basis of the complementary treatment concept (in-duction of cellular antioxidants, improved oxygen supply and immune modulation).

In this case, the application method of choice is Major Auto-Haemotherapy MAH with low O₂ concentrations between 10 and 15 µg/ml. Concentration measurement and control is here absolutely necessary!



As an alternative, the rectal insufflation method may also be applied.

The OZONOSAN photonik is ideal for use in the medical practice, especially in combination with the microbubble system for perfect distribution and reaction of ozone in the bload (extraorpareal bload treatment); this actually optimizes the application and the effect of low ozone concentrations.

Equally suitable for all systemic and topical forms of application, ozone concentrations between 2 and 75 µg/ml are available, with a water ozonation unit as separate module.

In pain therapy, the preferred concentrations are 2 to approx. 10 µg/ml (trigger points, tender points, subcutaneous, periarticular and other forms of injection).

alphaplus